AUS
NZ
UK
CA
USA
IND
Key Highlights
- Monogram Technologies received an Additional Information Request (AIR) from the FDA regarding its mBôs TKA System.
- The Company is committed to addressing the AIR while pursuing international clinical trials.
- Monogram recently closed a successful $13 million public offering to support its strategic initiatives.
Monogram Technologies Inc. (NASDAQ:MGRM), an innovative AI-driven robotics company, is making strides in orthopedic surgery with its mBôs Total Knee Arthroplasty (TKA) System. On September 30, 2024, the Company announced that it had received an Additional Information Request (AIR) from the U.S. Food and Drug Administration (FDA) concerning its 510(k) premarket filing for the mBôs TKA System. This development follows the initial submission of the Application on July 19, 2024, which had successfully passed the FDA’s administrative review.
The AIR indicates that the FDA has placed the Application on hold, pending Monogram's comprehensive response. The Company has been granted 180 days from the date of the AIR to provide the necessary information; otherwise, the FDA may withdraw the Application. Ben Sexson, CEO of Monogram Technologies, expressed optimism about the process, stating, “We believe this response provides more transparency for Monogram's path forward toward obtaining clearance and ultimately commercialization.”
Monogram’s leadership is keenly focused on ensuring that the Application adheres to FDA requirements as swiftly as possible. The Company recently completed a $13 million public offering, which was upsized and oversubscribed, strengthening its financial position to continue executing strategic objectives. With growing interest from surgeons and the market, Monogram remains committed to its vision of enhancing orthopedic robotics, emphasizing the value proposition of its active robotic system.
While working on the FDA response, Monogram plans to submit data for its active modality using clinical data collected outside the United States (OUS). This dual approach aims to expedite the regulatory process for both its semi-active and fully active robotic systems. Mr. Sexson highlighted the significance of surgeon feedback, stating that the Company is increasingly confident that its hands-free, fully active system could revolutionize the orthopedic surgery landscape.
Looking ahead, Monogram has outlined several upcoming milestones that are critical to its growth and regulatory ambitions. These include obtaining regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals, anticipated in early Q1 2025. The Company also plans to conduct OUS live-patient surgery trials, which will include 92 total knee replacement procedures with a three-month clinical follow-up. This data will be crucial for the FDA submission related to the mBôs TKA System.
Furthermore, Monogram is actively exploring and expanding its domestic and international relationships. The Company is set to exhibit at the Arab Health event in January 2025, further positioning itself in the global healthcare market.
In summary, Monogram Technologies is at a pivotal juncture as it navigates the regulatory landscape while advancing its groundbreaking robotic systems. With a robust financial backing and a clear strategic focus, the Company aims to secure FDA clearance and capitalize on its innovations in orthopedic surgery. The future looks promising as Monogram strives to enhance patient outcomes and reshape the standards of care in the industry.
